Charles Albright (Rodrique Ngowi, AP Images)

Ed­i­tas Med­i­cine's sci­ence head Al­bright leaves for new job just as biotech gets tri­al clear­ance for sick­le cell ther­a­py

Ed­i­tas Med­i­cine has re­ceived the FDA’s bless­ing to en­ter the clin­ic with its first ex vi­vo cell ther­a­py — but it will do so with­out CSO Charles Al­bright, who is leav­ing his post for the same gig at an ear­ly-stage com­pa­ny.

The FDA clear­ance was an­nounced min­utes af­ter Ed­i­tas shared word of Al­bright’s de­par­ture ear­ly Mon­day morn­ing. The bit­ter­sweet news caused the biotech’s stock $ED­IT to sink more than 12%, with shares hov­er­ing around $79 apiece.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.